Valeant Pharmaceuticals Intl Inc.: Should You Take a Contrarian Shot?

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is hitting new multi-year lows. Is the bottom in sight?

| More on:
The Motley Fool
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is now trading at lows not seen in more than six years.

Let’s take a look at the troubled Canadian drug company to see if the sell-off looks overdone.

Tough times

Valeant was briefly Canada’s most valuable company in the summer of 2015 when the stock surged above $300 per share, giving the company a market capitalization of more than $110 billion.

Today, investors can pick the stock up for less than $18, and the company’s market cap is about $6 billion.

The rapid decline is one of the worst investor wipeouts in the Canadian market, ranking up there with Nortel and BlackBerry.

New management has taken over to try to right the ship, but Valeant’s numbers continue to head in the wrong direction, and the massive debt load remains a challenge.

Valeant finished Q3 2016 with US$34 billion in debt. The company recently announced assets sales of US$2.1 billion, so steps are being taken to improve the balance sheet, but more work has to be done.

Results in Q3 missed analyst expectations. Adjusted earnings for the quarter came in at US$1.55 per share compared to the US$1.75 per share the market wanted to see.

Management said the Q4 2016 numbers were not going to be much better, so investors are somewhat concerned about how things will look when those results are released.

On top of that, patent expirations in 2017 could offset any improvements achieved as a result of the ongoing restructuring efforts.

Trump effect

President Trump has decided to include the drug makers in his group of targeted industries. In a January 31 meeting with CEOs of leading drug makers, he indicated he wants to reduce red tape and help get new drugs approved, but also wants to see lower prices and a return of manufacturing to the United States.

So, investors have to keep this in mind when evaluating Valeant and its peers.

Should you buy?

Fans of the stock say Valeant’s product pipeline and portfolio of top drugs are worth much more than the current valuation.

That might well be true, and if you have a contrarian investing style, a small position could be worth a shot.

At this point, however, there is simply too much political risk to call a bottom. I would at least wait for the Q4 numbers and 2017 guidance to come out before buying the stock.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Walker has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Investing

KM Throwaway Post

Read more »

Investing

Carlos Test Yoast Metadata

Read more »

Investing

KM Ad Test

This is my excerpt.

Read more »

Investing

Test post for affiliate partner mockups

Updated: 9/17/2024. This post was not sponsored. The views and opinions expressed in this review are purely those of the…

Read more »

Investing

Testing Ecap Error

Premium content from Motley Fool Stock Advisor We here at Motley Fool Stock Advisor believe investors should own at least…

Read more »

Investing

TSX Today: Testing the Ad for James

la la la dee dah.

Read more »

Lady holding remote control pointed towards a TV
Investing

2 Streaming Stocks to Buy Now and 1 to Run From

There are streaming stocks on the TSX that are worth paying attention to in 2023 and beyond.

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Stocks for Beginners

Top Recession-Resilient TSX Stocks to Buy With $3,000

It's time to increase your exposure to defensives!

Read more »